CN Patent

CN111467363A — 索非布韦在制备预防和治疗冠状病毒的药物中的应用

Assigned to Shenzhen Institute of Advanced Technology of CAS · Expires 2020-07-31 · 6y expired

What this patent protects

本发明公开了索非布韦在制备预防和治疗冠状病毒的药物中的应用，具体公开了索非布韦或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。所述的冠状病毒为新型冠状病毒SARS‑Cov‑2、SARS‑CoV、HCoV 229E、NL63、OC43、HKU1和MERS‑CoV。索非布韦对新冠肺炎新型冠状病毒的半数有效浓度为1.12μM，毒性低，具有一个良好的治疗窗口。

USPTO Abstract

本发明公开了索非布韦在制备预防和治疗冠状病毒的药物中的应用，具体公开了索非布韦或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。所述的冠状病毒为新型冠状病毒SARS‑Cov‑2、SARS‑CoV、HCoV 229E、NL63、OC43、HKU1和MERS‑CoV。索非布韦对新冠肺炎新型冠状病毒的半数有效浓度为1.12μM，毒性低，具有一个良好的治疗窗口。

Drugs covered by this patent

Patent Metadata

Patent number: CN111467363A
Jurisdiction: CN
Classification: —
Expires: 2020-07-31
Drug substance claim: No
Drug product claim: No
Assignee: Shenzhen Institute of Advanced Technology of CAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.